Bilayer Matrix Tablets for Prolonged Actions of Metformin Hydrochloride and Repaglinide

AAPS PharmSciTech

Volumn 16, Issue 2, 2014, Pages 344-353

  He, Wei ^a   Huang, Shijing ^b   Zhou, Chunyan ^a   Cao, Lin ^a   Yao, Jing ^a   Zhou, Jianping ^a   Wang, Guangji ^a   Yin, Lifang ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Third People's Hospital of Chengdu   (China)

Author keywords

bilayer tablets; metformin hydrochloride; pharmacokinetics; repaglinide; sustained release

Indexed keywords

CARBAMIC ACID DERIVATIVE; DELAYED RELEASE FORMULATION; DRUG COMBINATION; METFORMIN; PIPERIDINE DERIVATIVE; REPAGLINIDE; TABLET;

ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELAYED RELEASE FORMULATION; DOG; DRUG COMBINATION; MALE; MEDICINAL CHEMISTRY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TABLET;

ANIMALS; CARBAMATES; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOGS; DRUG COMBINATIONS; MALE; METFORMIN; PIPERIDINES; TABLETS;

EID: 84939889007     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-014-0229-1     Document Type: Article

References (33)

1. De Berardis G, Dttorre A, Graziano G, Lucisano G, Pellegrini F, Cammarota S, et al. The burden of hospitalization related to diabetes mellitus: a population-based study. Nutr Metab Cardiovasc. 2013;22(7):605–12.
2. Zuo H, Shi Z, Hussain A. Prevalence, trends and risk factors for the diabetes epidemic in China: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2014;103(2):176–85.
3. Guariguata L, Linnenkamp U, Beagley J, Whiting DR, Cho NH. Global estimates of the prevalence of hyperglycaemia in pregnancy. Diabetes Res Clin Pract. 2014;103(2):176–85.
4. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12(2):235–46.
5. Thomas CR, Turner SL, Jefferson WH, Bailey CJ. Prevention of dexamethasone-induced insulin resistance by metformin. Biochem Pharmacol. 1998;56(9):1145–450.
6. Wolffenbuttel BHR. Repaglinide: a new compound for the treatment of patients with type 2 diabetes. Neth J Med. 1999;55(5):229–34.
7. Tosi F, Muggeo M, Brun E, Spiazzi G, Perobelli L, Zanolin E, et al. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism. 2003;52(7):862–7.
8. Dailey GE. Glyburide/metformin tablets: a new therapeutic option for the management of type 2 diabetes. Expert Opin Pharmaco. 2003;4(8):1417–30.
9. Scott LJ. Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(2):249–72.
10. Dhana lekshmi UM, Poovi G, Kishore N, Reddy PN. In vitro characterization and in vivo toxicity study of repaglinide loaded poly (methyl methacrylate) nanoparticles. Int J Pharm. 2010;396(1–2):194–203.
11. Lalau JD, Azzoug ML, Kajbaf F, Briet C, Desailloud R. Metformin accumulation without hyperlactataemia and metformin-induced hyperlactataemia without metformin accumulation. Diabetes Metab. 2014;40(3):220–3.
12. Klinzing G, Zavaliangos A. Understanding the effect of environmental history on bilayer tablet interfacial shear strength. Pharm Res. 2013;30(5):1300–10.
13. Abebe A, Akseli I, Sprockel O, Kottala N, Cuitino AM. Review of bilayer tablet technology. Int J Pharm. 2014;461(1–2):549–58.
14. Qin C, He W, Zhu C, Wu M, Jin Z, Zhang Q, et al. Controlled release of metformin hydrochloride and repaglinide from sandwiched osmotic pump tablet. Int J Pharm. 2014;466(1–2):276–85.
15. Yin LF, Huang SJ, Zhu CL, Zhang SH, Zhang Q, Chen XJ, et al. In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier. Drug Dev Ind Pharm. 2012;38(11):1371–80.
16. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2012;64:163–74.
17. Wu B, Deng D, Lu Y, Wu W. Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. Eur J Pharm Biopharm. 2008;69(1):294–302.
18. Chambin O, Champion D, Debray C, Rochat-Gonthier MH, Le Meste M, Pourcelot Y. Effects of different cellulose derivatives on drug release mechanism studied at a preformulation stage. J Control Release. 2004;95(1):101–8.
19. Grund J, Körberr M, Bodmeier R. Predictability of drug release from water-insoluble polymeric matrix tablets. Eur J Pharm Biopharm. 2013;85(3):650–5.
20. Rujivipat S, Bodmeier R. Modified release from hydroxypropyl methylcellulose compression-coated tablets. Int J Pharm. 2010;402(1–2):72–7.
21. Quinten T, Gonnissen Y, Adriaens E, Beer TD, Cnudde V, Masschaele B, et al. Development of injection moulded matrix tablets based on mixtures of ethylcellulose and low-substituted hydroxypropylcellulose. Eur J Pharm Sci. 2009;37(3–4):207–16.
22. Sotthivirat S, Haslam JL, Lee PI, Rao VM, Stella VJ. Release mechanisms of a sparingly water-soluble drug from controlled porosity-osmotic pump pellets using sulfobutylether-beta-cyclodextrin as both a solubilizing and osmotic agent. J Pharm Sci. 2009;98(6):1992–2000.
23. Palmer D, Levina M, Nokhodchi A, Douroumis D, Farrell T, Rajabi-Siahboomi A. The influence of sodium carboxymethylcellulose on drug release from polyethylene oxide extended release matrices. AAPS PharmSciTech. 2011;12(3):862–71.
24. Conti S, Maggi L, Segale L, Ochoa Machiste E, Conte U, Grenier P, et al. Matrices containing NaCMC and HPMC 1. Dissolution performance characterization. Int J Pharm. 2007;333(1–2):136–42.
25. Maderuelo C, Zarzuelo A, Lanao JM. Critical factors in the release of drugs from sustained release hydrophilic matrices. J Control Release. 2011;154(1):2–19.
26. Vaidya MP, Avachat AM. Investigation of the impact of insoluble diluents on the compression and release properties of matrix based sustained release tablets. Powder Technol. 2011;214(3):375–81.
27. Fuertes I, Caraballo I, Miranda A, Milln M. Study of critical points of drugs with different solubilities in hydrophilic matrices. Int J Pharm. 2010;383(1–2):138–46.
28. Mandi Z, Gabelica V. Ionization, lipophilicity and solubility properties of repaglinide. J Pharm Biomed Anal. 2006;41(3):866–71.
29. American Chemical Society. 2014. https://scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf.
30. Bettini R, Catellani PL, Santi P, Massimo G, Peppas NA, Colombo P. Translocation of drug particles in HPMC matrix gel layer: effect of drug solubility and influence on release rate. J Control Release. 2001;70(3):383–91.
31. Vidon N, Chaussade S, Noel M, Franchisseur C, Huchet B, Bernier JJ. Metformin in the digestive tract. Diabetes Res Clin Pract. 1988;4(3):223–9.
32. Nayak AK, Pal D, Santra K. Tamarind seed polysaccharide-gellan mucoadhesive beads for controlled release of metformin HCl. Carbohydr Polym. 2014;103:154–63.
33. Kortejrvi H, Mikkola J, Bckman M, Antila S, Marvola M. Development of level A, B and C in vitro–in vivo correlations for modified-release levosimendan capsules. Int J Pharm. 2002;241(1):87–95.